Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.580
0.00 (0.00%)
At close: May 15, 2026, 4:00 PM EDT
3.480
-0.100 (-2.79%)
After-hours: May 15, 2026, 7:57 PM EDT
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or -74.37% compared to the previous year.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,529,210
Profits / Employee
$794,951
Market Cap
148.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -235 | -74.37% |
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Molecular Partners AG | 134 |
| Alps Group | 93 |
| Pyxis Oncology | 56 |
| Korro Bio | 49 |
| TuHURA Biosciences | 22 |
| Black Diamond Therapeutics | 21 |
| Galectin Therapeutics | 9 |
AGEN News
- 9 hours ago - Agenus announces publication of Phase 1b BOT+BAL data - TheFly
- 9 hours ago - Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - Business Wire
- 4 days ago - Agenus reports Q1 revenue $33.7M vs. $24.1M last year - TheFly
- 4 days ago - Agenus provides 2026 strategic priorities - TheFly
- 4 days ago - Agenus announces conclusion of SEC investigation with no enforcement action - TheFly
- 4 days ago - Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development - Business Wire
- 11 days ago - Agenus to Provide First Quarter 2026 Financial Report and Corporate Update - Business Wire
- 24 days ago - Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 - Business Wire